Xiaoyu Qian, MSc

Takeda Pharmaceutical Company, Shanghai, China, China

Poster(s):

• P3242 - Vedolizumab Demonstrated Significant Improvements in Symptomatic Relief and Quality of Life in Patients With Crohn’s Disease: Results from VALUE, a Prospective, Multicenter, Observational Study
  Monday, October 27, 2025

  10:30 AM - 4:00 PM PDT